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The primary driver of health care costs for patients with community-acquired pneumonia (CAP) is the hospital length of stay
(LOS). Unfortunately, hospital LOS comparisons are difficult to make from phase III CAP trials because of their structured de-
signs and prespecified treatment durations. However, an opportunity still exists to draw inferences about potential LOS differ-
ences between treatments through the use of surrogates for hospital discharge. The intent of this study was to quantify the time
to a clinical response, a proxy for the time to discharge readiness, among hospitalized CAP patients who received either ceftaro-
line or ceftriaxone in two phase III CAP FOCUS clinical trials. On the basis of the Infectious Diseases Society of America and
American Thoracic Society CAP management guidelines and recent FDA guidance documents for community-acquired bacterial
pneumonia, a post hoc adjudication algorithm was constructed a priori to compare the time to a clinical response, a proxy for the
time to discharge readiness, between patients who received ceftaroline or ceftriaxone. Overall, 1,116 patients (ceftaroline, n 
562; ceftriaxone, n  554) from the pooled FOCUS trials met the selection criteria for this analysis. Kaplan-Meier analyses
showed that ceftaroline was associated with a shorter time, measured in days, to meeting the clinical response criteria (P  0.03).
Of the patients on ceftaroline, 61.0, 76.1, and 83.6% achieved a clinical response by days 3, 4, and 5, compared to 54.3, 69.8, and
79.3% of the ceftriaxone-treated patients. In the Cox regression, ceftaroline was associated with a shorter time to a clinical re-
sponse (HR, 1.16, P  0.02). The methodology employed here provides a framework to draw comparative effectiveness infer-
ences from phase III CAP efficacy trials. (The FOCUS trials whose data were analyzed in this study have been registered at
ClinicalTrials.gov under registration no. NCT00621504 and NCT00509106.)
Community-acquired pneumonia (CAP) remains the leadinginfection-related cause of death in the United States (1–3).
Treatment of CAP places a tremendous burden on the health care
system. It is estimated that the annual treatment cost of CAP ex-
ceeds $8.4 billion, largely because of hospitalization costs (4). This
statistic is particularly concerning, given that hospitalization
events due to all causes of pneumonia are projected to double to
2.6 million from 2004 to 2040, partly because of the aging popu-
lation (5). Given that inpatient care for CAP costs approximately
20 times more than outpatient care (6), identifying therapies that
facilitate the timely discharge of stable patients is essential to re-
ducing the overall cost of CAP treatment.
Phase III international, multicenter, randomized, double-blind,
comparative clinical trials are the current gold standard for estab-
lishing the efficacy and safety profiles of new antibiotics for CAP
(7, 8). Although efficacy is established in such a design setting, it is
difficult to infer meaningful economic or effectiveness differences
between treatments in such trials. It is well documented that the
primary driver of health care costs for patients with CAP is the
hospital length of stay (LOS) (3, 6). Unfortunately, it is difficult to
make direct hospital LOS comparisons in phase III registration
studies. These studies are international, and the clinical practices
and health care reimbursement policies in the countries repre-
sented dictate the hospital LOS of the study participants. Further
mitigating LOS comparisons in most phase III trials are the fixed
therapy duration requirements, lack of oral step-down therapy,
and lack of predefined criteria for hospital discharge (9–11).
Although crude hospital LOS comparisons are difficult to in-
terpret, it is possible to infer LOS differences between treatment
groups of phase III trials through the use of proxy criteria for
hospital discharge. Criteria for a dischargeable patient with CAP
are well described in the American Thoracic Society/Infectious
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Diseases Society of America (ATS/IDSA) CAP clinical manage-
ment guidelines (4), which are consistent with the definitions of a
favorable clinical response in the recent FDA CAP guidance doc-
uments (7, 8). Since data on vital signs, symptom resolution, lab-
oratory values, and clinical responses are collected daily in most
phase III CAP trials, it is possible to bridge trial results to the
real-world practice setting by objectively defining the criteria for
clinical response, a proxy for a dischargeable patient, with the
existing clinical data.
The intent of this study was to quantify the time to a clinical
response, a proxy for the time to discharge readiness, among hos-
pitalized CAP patients who received either ceftaroline fosamil
(ceftaroline here) or ceftriaxone in two phase III trials (9–11). To
do so, we constructed an objective definition a priori (i.e., prior to
the start of the present study) to post hoc adjudicate a discharge-
able patient on the basis the criteria set forth in the ATS/IDSA
guidelines and FDA briefing documents (4, 7, 8). To ensure uni-
formity with the recent FDA guidance for CAP, the definition of a
dischargeable patient employed in this analysis was identical to the
early clinical response outcome variable used in the FDA-specified
day 4 clinical response analysis of ceftaroline versus ceftriaxone for
community-acquired bacterial pneumonia (CABP) (12). With
this definition in place at the start of the present study, we com-
pared ceftaroline and ceftriaxone-treated patient groups for the
time to a clinical response, a proxy for time to discharge readiness,
by using time-to-event analyses. As secondary objectives, we com-
pared treatment groups for the time to clinical stability and im-
provement of at least one symptom with no deterioration from
the baseline.
(This study was presented in part at CHEST 2013 [26 to 31
October 2013, Chicago, IL], and at IDWeek 2013 [2 to 6 October
2013, San Francisco, CA].)
MATERIALS AND METHODS
Study population. Data from two phase III clinical trials with similar
study designs were pooled for the present study. The trials of ceftaroline
community-acquired pneumonia trial versus ceftriaxone in hospitalized
patients (FOCUS 1 and FOCUS 2) were double-blind, randomized, mul-
tinational, multicenter studies that compared the safety and efficacy of
intravenous (i.v.) ceftaroline versus i.v. ceftriaxone in adults who were
hospitalized with CAP but not admitted to an intensive care unit (9–11).
Both trials required patients to be in Pneumonia Outcomes Research
Team (PORT) risk class III or IV at the time of hospital admission to be
considered in the modified intent-to-treat efficacy (MITTE) analysis (19).
Patients were randomized (1:1) to receive 600 mg of ceftaroline every 12 h
or 1g of ceftriaxone every 24 h for 5 to 7 days. Patients in FOCUS 1 were
also orally administered 500 mg of clarithromycin every 12 h on day 1
(10). The FOCUS trial protocols specified that daily clinical signs and
symptoms be recorded on case report forms (CRFs) while patients were
on the study drug; all patients were assessed as clinical cure, clinical fail-
ure, or indeterminate at the end-of-therapy (EOT) visit (9–11).
Details of the FOCUS trial designs and patient population definitions
are available elsewhere (9–11). The sample used in the present study in-
cluded all of the patients in the clinically evaluable (CE) population (n 
908), a subset of the MITTE population (n  1,153). Additionally, 208 of
the 245 patients in the MITTE population who did not meet the criteria
for the CE population were included in our study sample because of the
adequacy of data availability given the current focus on effectiveness eval-
uation for this analysis. These 208 patients included individuals with (i) an
atypical sole causative pathogen or infection with Legionella pneumophila,
(ii) less than 80% compliance, (iii) a test-of-cure (TOC) window (8 to 15
days after the EOT visit) violation, (iv) indeterminate response at TOC
and not a clinical failure at EOT, and (v) missing assessment at TOC and
not a clinical failure at EOT. The sample criteria of the present analysis
were agreed upon by an adjudication committee (a panel of four physi-
cians with expertise in CAP [Antonio Anzeuto, Andrew Shorr, David
Weber, and Thomas File]) and the study’s principal investigator (Thomas
Lodise) prior to the blinded automated and manual adjudications.
Definitions of clinical response, clinical stability, symptom im-
provement and post hoc adjudication. The definitions of clinical re-
sponse (a proxy for discharge readiness), clinical stability, and symptom
improvement, and alternative criteria for sensitivity analyses are provided
in Table 1. Consistent with the early clinical response outcome variable
used in the FDA-specified day 4 clinical response analysis of ceftaroline
versus ceftriaxone for CABP (12), achievement of a clinical response, or
discharge readiness, required that both the clinical stability and symptom
improvement criteria be met. Clinical vital signs included temperature,
heart rate, systolic blood pressure, respiratory rate, oxygen saturation, and
mental status. Symptoms included cough, dyspnea, chest pain, and spu-
tum production. The adjudication algorithm was applicable up to day 7,
after which clinical vital signs and symptoms were not available on CRFs.
Sensitivity analyses were performed on the basis of discussions of the
adjudication committee prior to finalization of the statistical analysis plan
and initiation of the study. Since CAP often occurs in patients with base-
line confusion or disorientation, the committee believed it was prudent to
rerun the analyses with removal of this variable to assess the robustness of
the findings. Given the reader variability in respiratory rate measurement
in clinical practice, the committee also felt it was prudent to perform a
sensitivity analysis that includes a more stringent definition of a high
respiratory rate. The two-symptom improvement was another committee
recommendation to assess the robustness of the data.
The adjudication algorithm was applied to the pooled FOCUS data by
using a systematic approach to perform automated adjudication on a
per-day basis starting on day 2 (see Appendix SA in the supplemental
material). Patients were considered to have achieved a clinical response
and to be dischargeable on the first day on which they met all of the
criteria. If they failed to meet all of the criteria by day 7, patients were
considered clinical failures on day 7 and censored in the time-to-event
analyses. For patients with missing data on all of the criterion measures on
any day and onward, the clinical response or dischargeability date was
determined on the basis the EOT assessment on the CRF. If clinical cure or
indeterminate was documented, the patient was censored on the last day
TABLE 1 Clinical stability and symptom criteria for primary and
sensitivity analyses of time to discharge readiness
Clinical stability
criterion Primary analysis Sensitivity analysesa
Temp (°C) 37.8 37.8







% Oxygen saturation 90 90
Normal mental statusb Present Not assessed
Symptom assessmentc At least 1 symptom improved
and no deterioration from
baseline




a There were three individual sensitivity analyses for the following criteria: excluding
normal mental status, a respiratory rate of 30 breaths/min, and at least two symptom
improvements with no deterioration from the baseline.
b Defined as absence of confusion/disorientation.
c Cough, dyspnea, and chest pain were assessed as absent, mild, moderate, or severe.
Sputum was assessed as absent or present. If present at the baseline, a change in
character from the baseline was also recorded as improved, unchanged, or worsened.
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that data were available. If clinical failure was documented, the patient was
censored at day 7. The automated process could not adjudicate those cases
with partial missing data on any date. These cases were manually adjudi-
cated by the adjudication committee by using the same adjudication al-
gorithm along with clinical judgment. The entire adjudication process
was blinded to treatment assignment.
Statistical analysis. Details of baseline patient characteristics were re-
ported and compared between treatment arms, including demographics,
medical history, physical examination, laboratory findings, prior antibi-
otic therapy, previous episodes of pneumonia, severity of illness (calcu-
lated by means of the PORT risk class scoring system and CURB-65 [con-
fusion, urea, respiratory, blood pressure, age of 65 years] rating scale),
microbiological culture results, and concomitant antibiotic treatment
(19, 20). Kaplan-Meier time-to-event analyses (log rank test) were used to
characterize the primary outcomes of interest stratified by treatment arm.
In addition, sensitivity analyses were conducted (Table 1). Kaplan-Meier
analyses of time to clinical response, a proxy for time to discharge readi-
ness, were also conducted for the following subgroups: (i) Gram-positive
infection only, (ii) Gram-negative infection only, (iii) typical pathogen(s)
only, (iv) atypical pathogen(s) only, (v) no pathogen, (vi) Streptococcus
pneumoniae, (vii) methicillin-susceptible Staphylococcus aureus (MSSA),
(viii) PORT risk class III, (ix) PORT risk class IV, (x) CURB-65 score of
2, (xi) CURB-65 score of 2, (xii) FOCUS 1, and (xiii) FOCUS 2. Cox
proportional-hazard models were used to estimate the hazards of time to
clinical response, time to clinical stability, and time to symptom improve-
ment, controlling for baseline characteristics (age of 65 years, gender,
region of enrollment, prior pneumonia, current/recent alcohol abuse,
prior antibiotic use, and PORT classification). All analyses were per-
formed in SAS version 9.2 (SAS, Cary, NC).
RESULTS
Patient characteristics. There were 1,116 patients (ceftaroline,
n  562 [50.4%]; ceftriaxone, n  554 [49.6%]) from the pooled
FOCUS trials who met the selection criteria and were included in
the study sample. The clinical-stability and symptom data for
1,002 (89.8%) of the 1,116 patients included were complete. The
majority of these patients (n  947, 84.9% of the total study pop-
ulation) achieved a clinical response (i.e., were ready to discharge)
by day 7. There were 89 patients (8.0%) with missing vital and
symptom data on a day before day 7. Among these patients, 50 had
a clinical cure or indeterminate result documented on CRFs at the
EOT visit and were censored on the last day when the vital and
symptom data were available; 39 were documented in the CRFs
with clinical failure at the EOT visit and were censored on day 7.
The remaining 25 (2.2%) patients had partial missing data and
were adjudicated manually.
The study sample baseline characteristics are summarized in
Table 2. Nearly half of the patients were 65 years old or older
(mean, 61 years old). Slightly over 60% of the patients were male,
and more than 90% of them were white. Over one-third of the
patients were in PORT risk class IV. The two treatment groups
were comparable for all of the baseline characteristics except the
percentage who had any prior incidents of pneumonia. More pa-
tients in the ceftaroline group than in the ceftriaxone group had a
prior pneumonia diagnosis (21.4% versus 15.7%, P  0.015).
Time to clinical response, clinical stability, and symptom im-
provement. Kaplan-Meier analyses showed that the time to a clin-
ical response (i.e., discharge readiness) was statistically signifi-
cantly shorter among patients treated with ceftaroline than among
patients treated with ceftriaxone (Fig. 1, top; P  0.0335). The
time to clinical stability was also statistically significantly shorter
among patients treated with ceftaroline (Fig. 1, middle; P 
0.0190). Patients treated with ceftaroline had a nonsignificantly
shorter time to the improvement of at least one clinical symptom
without deterioration from the baseline (Fig. 1, bottom). Of the
562 ceftaroline-treated patients, 61.0, 76.1, and 83.6% achieved a
clinical response by days 3, 4, and 5, compared to 54.3, 69.8, and
79.3%, respectively, of the 554 ceftriaxone-treated patients. The
corresponding Kaplan-Meier estimated median time to the achieve-
ment of a clinical response was 3 (2 to 3) days for the ceftaroline group
and 3 (2 to 4) days for the ceftriaxone group.
Three sensitivity analyses of the time to a clinical response us-
ing alternative adjudication criteria (excluding mental health sta-
tus, a respiratory rate of 30 breaths/min, and requiring two
symptoms to improve from the baseline with no deterioration)
showed consistent results; patients treated with ceftaroline had a
shorter time to a clinical response than patients treated with ceftri-
axone (for Kaplan-Meier plots of the sensitivity analyses, see Ap-
pendix SB in the supplemental material).
Table 3 presents the results of the subgroup analyses for the
median time to a clinical response. For Kaplan-Meier plots of
subgroups, see Appendix SC in the supplemental material.
Among patients with Gram-positive infections only and patients
in PORT risk class III, patients who received ceftaroline had a
shorter median time to a clinical response. While the difference
was not statistically significant, the time to a clinical response was
numerically in favor of ceftaroline in the following subsets: Strep-
tococcus pneumoniae (P  0.0585), no baseline pathogen lab re-
sults (P  0.0680), CURB-65 score of 2 (P  0.0533), and
FOCUS 1 (P  0.0578). Similar median numbers of days to a
clinical response were noted for other subgroups (Table 3).
Cox proportional-hazard models. Table 4 presents the results
of the study outcomes using Cox proportional-hazard models ad-
justing for baseline characteristics. The findings are consistent
with the Kaplan-Meier analyses. After adjustment for potential
confounding factors, ceftaroline was associated with a 16% greater
chance of a clinical response at any time point starting on day 2
(hazard ratio [HR], 1.161; 95% confidence interval [CI], 1.022 to
1.319 [P  0.022]) compared with ceftriaxone. Ceftaroline was
associated with an 18% greater chance of achieving clinical stabil-
ity at any time point than ceftriaxone (HR, 1.179; 95% CI, 1.040 to
1.338 [P  0.010]).
DISCUSSION
Given the exigent clinical need for meaningful comparative effec-
tiveness data on CAP therapies, this study compared patients re-
ceiving ceftaroline and patients receiving ceftriaxone in two phase
III FOCUS CAP registration trials for the time to a clinical re-
sponse, a proxy for the time to discharge readiness. To ensure
uniformity with the ATS/IDSA CAP clinical management guide-
lines and recent FDA guidance for CAP, the definition of a clinical
response, a proxy for a dischargeable patient, employed in this
analysis was determined prior to the start of the study and was
identical to the early clinical response outcome variable used in
the FDA-specified day 4 clinical response analysis of ceftaroline
versus ceftriaxone for CABP (12). Through the use of the a priori-
constructed post hoc adjudication algorithm, patients who re-
ceived ceftaroline were found to have shorter overall times to a
clinical response and clinical stability relative to patients who re-
ceived ceftriaxone. Of the 562 ceftaroline-treated patients, 61.0,
76.1, and 83.6% achieved a clinical response by days 3, 4, and 5,
compared to 54.3, 69.8, and 79.3%, respectively, of the 554 ceftri-
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(n  554) P valued
Mean age (yr)  SD 60.65  16.30 61.31  15.69 0.5291
No. (%) 65 yr old 261 (46.44) 266 (48.01) 0.5987
No. (%) of males 351 (62.46) 354 (63.90) 0.6172
No. (%) of following race: 0.9924
Caucasian 520 (92.53) 515 (92.96)
Asian 19 (3.38) 19 (3.43)
Black 17 (3.02) 14 (2.53)
Native American/Alaskan 5 (0.89) 5 (0.90)
Other 1 (0.18) 1 (0.18)
No. (%) from following enrollment region: 0.9987
Africa 17 (3.02) 17 (3.07)
Asia 18 (3.20) 18 (3.25)
Eastern Europe 255 (45.37) 257 (46.39)
Latin America 62 (11.03) 59 (10.65)
USA 11 (1.96) 12 (2.17)
Western Europe 199 (35.41) 191 (34.48)
No. (%) with following most-common comorbidities:
Structural lung diseasea 154 (27.40) 139 (25.09) 0.3802
Any prior pneumonia 120 (21.35) 87 (15.70) 0.0152
Asthma 48 (8.54) 37 (6.68) 0.2410
Current or recent alcohol abuse 23 (4.09) 12 (2.17) 0.0649
Gastroesophageal reflux 23 (4.09) 16 (2.89) 0.2733
No. (%) with following smoking history:
Never smoked 265 (47.15) 278 (50.18)
Smoked but not current smoker 148 (26.33) 143 (25.81) 0.5359
Current smoker 149 (26.51) 133 (24.01)
No. (%) in PORT risk class:
III 351 (62.46) 344 (62.09) 0.9008
IV 211 (37.54) 210 (37.91)
No. (%) with CURB-65 score of:b
0 70 (12.46) 58 (10.47) 0.2983
1 213 (37.90) 233 (42.06)
2 222 (39.50) 195 (35.20)
3 51 (9.07) 59 (10.65)
4 6 (1.07) 9 (1.62)
No. (%) with bacteremia 22 (3.91) 19 (3.43) 0.6667
No. (%) with renal impairmentc
Mild (CLCR,
f 51–80 ml/min) 187 (33.27) 178 (32.13) 0.6838
Moderate (CLCR, 31–50 ml/min) 80 (14.23) 78 (14.08) 0.9406
No. (%) with WBC count (cells/mm3) of:c
4,500 25 (5.48) 28 (6.25) 0.6233
4500–10,000 207 (45.39) 215 (47.99) 0.4340
10,000 224 (49.12) 205 (45.76) 0.3112
No. (%) with immature-neutrophil (band) percentage
of:
10 9 (1.99) 5 (1.13) 0.2965
15 6 (1.33) 3 (0.68) 0.5058
No. (%) with prior antibiotic usee 229 (40.75) 248 (44.77) 0.1749
a Defined as any chronic parenchymal or airway disease (e.g., chronic obstructive pulmonary disease [emphysema, chronic bronchitis], bronchiectasis, or interstitial fibrosis).
b Scores ranged from 0 to 5, and the presence of each of the following contributed 1 unit to the score: new onset of confusion, urea greater than 7 mmol/liter, respiratory rate 30
breaths/min, systolic blood pressure of 90 mm Hg or diastolic blood pressure of 60 mm Hg, age of 65 years.
c Proportions for white blood cell (WBC) and immature neutrophil counts do not account for patients with missing data.
d P values were calculated by using Wilcoxon rank sum tests for continuous variables and chi-square tests for categorical variables.
e Antibiotic use within 96 h prior to first dose of study drug.
f CLCR, creatinine clearance.
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axone-treated patients. The results of the sensitivity analyses were
consistent with the core analyses, and the relationship between
ceftaroline and the time to a clinical response persisted in the Cox
regression analysis after adjustment for potential confounding
factors. Compared to ceftriaxone, ceftaroline was associated with
a 16% greater chance of a patient achieving a clinical response or
being discharged at any time starting on day 2. In the subgroup
analyses, patients with only a Gram-positive organism(s) at the
baseline and patients in PORT risk class III who received ceftaro-
line took less time to meet the clinical response criteria, while the
other subgroups showed comparable findings across the treat-
ment arms. Collectively, these findings indicate that ceftaroline
may be associated with a shorter time to a clinical response, a
proxy for the time to discharge readiness, relative to that seen with
FIG 1 Times to discharge readiness, clinical stability, and the improvement of at least one symptom. Top, time to discharge readiness; middle, time to clinical
stability; bottom, time to the improvement of at least one symptom with no symptom deterioration from the baseline.
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ceftriaxone. While cumulative daily achievement of a clinical re-
sponse was only marginally different between treatment groups
overall, more pronounced differences in the time to a clinical re-
sponse between treatment groups were observed among patients
with S. pneumoniae or other non-methicillin-resistant S. aureus
(MRSA) susceptible Gram-positive organisms at the baseline.
These findings have important implications for clinicians.
Time to clinical stability has been widely accepted as a tool to
guide the switch from i.v. to oral antibiotic therapy in hospitalized
patients, as well as to judge appropriateness for hospital discharge
(4). A number of studies have demonstrated that there is a clear
link between the time to a clinical response (e.g., clinical stability
and symptom improvement) and subsequent hospital discharge
and outcomes among hospitalized patients with CAP (13–15).
Using a definition of response nearly identical to our time to dis-
charge readiness criterion, Zasowski and colleagues were able to
conclusively demonstrate a monotonic relationship between the
time to a clinical response and the hospital LOS among PORT risk
class III and IV hospitalized adult CAP patients who received
ceftriaxone and azithromycin (15). On average, patients were dis-
TABLE 3 Subgroup analyses of time to discharge readiness
Subgroup













Positive only 3 (2, 4) 71 (12.6) 4 (3, 6) 68 (12.3) 0.0094
Negative only 3 (3, 5) 109 (19.4) 3 (3, 5) 103 (18.6) 0.9250
Type of pathogen
Typical only 3 (2, 5) 143 (25.4) 3 (3, 5) 140 (25.3) 0.3046
Atypical only 3 (2, 5) 69 (12.3) 3 (2, 5) 60 (10.8) 0.7825
No baseline pathogen 3 (2, 4) 327 (58.2) 3 (2, 5) 327 (59.0) 0.0680
Streptococcus pneumoniae 3 (2, 4) 67 (11.9) 3 (2, 6) 68 (12.3) 0.0585
MSSA 4 (3, 6) 26 (4.6) 4 (3, 6) 28 (5.1) 0.5083
PORT risk score of:
III 3 (2, 4) 351 (62.5) 3 (2, 5) 344 (62.1) 0.0185
IV 3 (2, 5) 211 (37.5) 4 (3, 5) 210 (37.9) 0.6313
CURB-65 score of:
2 3 (2, 4) 283 (50.4) 3 (2, 5) 291 (52.5) 0.3073
2 3 (2, 5) 279 (49.6) 4 (2, 5) 263 (47.5) 0.0533
Trial
FOCUS 1 3 (2, 4) 281 (50.0) 3 (3, 5) 289 (52.2) 0.0578
FOCUS 2 3 (2, 4) 281 (50.0) 3 (2, 5) 265 (47.8) 0.2559
a Excluding Mycoplasma pneumoniae.
b Median number of days to achievement of a clinical response. Q1, quartile 1; Q3, quartile 3.
TABLE 4 Cox proportional-hazard models for primary and secondary outcomes
Parameter
Time to being dischargeable Time to clinical stability Time to one symptom improving
HR 95% CI P valuea HR 95% CI P valuea HR 95% CI P valuea
Ceftaroline vs ceftriaxone 1.161 (1.022, 1.319) 0.022d 1.179 (1.040, 1.338) 0.010d 1.123 (0.992, 1.271) 0.068
Age 65 vs age 65 1.030 (0.899, 1.179) 0.672 1.172 (1.027, 1.339) 0.019d 0.828 (0.727, 0.944) 0.005d
Male vs female 1.023 (0.895, 1.169) 0.743 1.032 (0.905, 1.177) 0.636 1.065 (0.935, 1.213) 0.342
Region of enrollmentb
Western Europe 1.147 (0.990, 1.329) 0.068 1.202 (1.041, 1.387) 0.012d 1.227 (1.063, 1.416) 0.005d
United States 1.689 (1.083, 2.635) 0.021d 2.199 (1.407, 3.437) 0.001d 1.146 (0.735, 1.787) 0.549
Otherc 1.205 (1.004, 1.448) 0.046d 1.204 (1.005, 1.443) 0.044d 1.244 (1.040, 1.489) 0.017d
Any prior pneumonia 1.019 (0.864, 1.202) 0.819 1.007 (0.856, 1.184) 0.933 0.984 (0.837, 1.157) 0.847
Current/recent alcohol abuse 0.731 (0.498, 1.073) 0.110 0.908 (0.627, 1.316) 0.611 0.742 (0.515, 1.068) 0.108
Prior antibiotic use 1.106 (0.970, 1.260) 0.132 1.050 (0.923, 1.194) 0.458 1.026 (0.903, 1.165) 0.694
PORT risk class III vs IV 1.284 (1.114, 1.480) 0.001d 1.353 (1.176, 1.556) 0.001d 0.922 (0.804, 1.057) 0.243
a P values were obtained by chi-square test.
b Reference category, Eastern Europe.
c Including Africa, Asia, and Latin America.
d Significant difference at the 5% level.
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charged 2 days following the achievement of a clinical response.
The lag between the time to a clinical response and subsequent
hospital discharge was not unexpected and was likely related to
administrative and social factors that often determine the ultimate
day of hospital discharge (16). Similarly, Halm et al. found a clear
link between the time to clinical stability, defined as normalization
of temperature, heart rate, and oxygen saturation, and the subse-
quent hospital LOS among hospitalized CAP patients (14). Simi-
lar to the study by Zasowski and colleagues (15), they also ob-
served a predictable lag between the achievement of stability and
subsequent hospital discharge (14). There are also some indica-
tions that time to clinical stability and being dischargeable may be
important determinants of subsequent hospital readmission and
death. Collectively, several recent studies (13–15) and the criteria
for a dischargeable CAP patient in the ATS/IDSA CAP clinical
management guidelines (4), which are nearly identical to the early
clinical response outcome variable used in the FDA-specified day
4 clinical response analysis of ceftaroline versus ceftriaxone for
CABP (12), lay the foundation for the clinical relevance of our post
hoc adjudication analyses.
Several issues should be taken into consideration when inter-
preting these findings. First, we applied a post hoc adjudication
algorithm to the data collected in the FOCUS trials, which is sub-
ject to all of the limitations inherent to a post hoc study. To mini-
mize the potential biases associated with this approach, we con-
structed a set of objective criteria for the time to a clinical
response, a proxy for discharge readiness, prior to conducting the
study and made the discharge readiness definition identical to the
early clinical response outcome variable used in the FDA-specified
day 4 clinical response analysis of ceftaroline versus ceftriaxone for
CABP (12). Furthermore, we applied an automated adjudication
process for nearly 98% of the patients included. For the remaining
2% of the cases, a standardized, treatment-blinded manual adju-
dication process was created to evaluate the time to a clinical re-
sponse or discharge readiness. The low percentage of manual
reviews, combined with the standardization of the process, mini-
mized the risk of biases resulting from the manual adjudication
process. Multivariate analyses were also performed to control for
any residual baseline differences.
This study was constrained by the original clinical trial study
design, which only required the collection of daily clinical infor-
mation for up to 7 days (the maximum dosing duration). Ideally,
a prospectively designed trial to address the analysis employed
here would have followed subjects daily until all of the discharge
criteria were met, well beyond 7 days, if necessary. Since the over-
whelming majority of the patients were adjudicated through an
automated process to be dischargeable by day 7, the available data
were still valuable in our study. In addition, measurements that
were used to determine clinical response were made daily but not
necessarily at the same time each day. While it is likely that clinical
response assessments were performed at similar times each day,
the intervals between daily clinical response measurements could
have been as short as 12 h or as long as 36 h. Therefore, caution
should be exercised when interpreting and differentiating daily
findings across treatments.
It is also important to recognize that concomitant clarithromy-
cin therapy was only permitted in FOCUS 1 and limited to the
initial 24 h of hospital admission (9–11). Dual beta-lactam–mac-
rolide therapy is the standard of care for CAP in the United States,
as recommended by the Joint Commission on Accreditation of
Health Care Organizations, Centers for Medicare & Medicaid Ser-
vices, and ATS/IDSA (4, 17). Cognizant of this, we incorporated
two analyses in this study to examine the potential effect of 1 day of
concomitant clarithromycin therapy. First, we compared the time
to a clinical response by trial (FOCUS 1 versus FOCUS 2). Second,
we did a restricted analysis that included patients only with atyp-
ical pathogens and examined the time to a clinical response or
readiness to discharge (non-treatment specific) by trial. Overall,
similar times to a clinical response were noted across the trials.
When restricted to only atypical pathogens by trial (FOCUS 1, n 
63; FOCUS, 2 n  66), the result favored FOCUS 1 (P  0.0267).
At day 4, 81% of the patients in FOCUS 1 were clinical responders
or discharge ready, compared to 64% of the patients in FOCUS 2.
This result was consistent with the subset analysis by File et al. that
demonstrated that 1 day of clarithromycin therapy was beneficial
to CAP patients with atypical pathogens only (18). Clearly, these
findings highlight the need for additional randomized studies to
assess the true effect of dual beta-lactam–macrolide therapy on
reported outcomes of the patients with CAP due to atypical patho-
gens only. Beyond the considerations mentioned above, it is im-
portant to recognize that no patients with MRSA were included in
this study. Therefore, no inferences can be made about patients
with CAP due to MRSA from this study. Statistically significant
differences were noted between study groups, but the absolute
differences between groups tended to be moderate. Lastly, one
must consider the overall cost of hospital care, the comparative
ceftaroline and ceftriaxone acquisition costs, and potential resis-
tance implications of using ceftaroline or ceftriaxone when apply-
ing these study results to their clinical practice.
In conclusion, the findings of this post hoc examination of the
clinical data collected from the FOCUS trials show that patients
who received ceftaroline took statistically significantly less time,
albeit modest, to meet the criteria for a clinical response, a proxy
for discharge readiness, than those who received ceftriaxone.
Given the clear link between the time to clinical stability and hos-
pital discharge (13–15), these findings may have implications for
clinical practice, as ceftaroline may be associated with a shorter
time to hospital discharge than that achieved with ceftriaxone
among hospitalized patients with CAP, particularly those with
only a Gram-positive pathogen(s) at the baseline. The methodol-
ogy employed here also provides a framework from which to draw
comparative effectiveness inferences from phase III CAP efficacy
trials. Since this was a post hoc examination of phase III clinical
trial data, the findings need to be validated in the clinical arena to
truly delineate their real-world implications.
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